Pancreatic Cancer Research

ResearcherGhent University HospitalActive in the last 2 years

Karen Paula Geboes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1003-666X; OpenAlex author ID A5020227571, A5136030553. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 9

  1. Longitudinal assessment of health-related quality of life in patients with borderline and locally advanced pancreatic cancer undergoing neoadjuvant FOLFIRINOX … Co-author DOI 10.1007/s00423-026-04121-3↗
  2. Success rate of salvage neoadjuvant chemotherapy for unexpectedly identified locally advanced pancreatic ductal adenocarcinoma during surgical exploration. Co-author DOI 10.1016/j.hpb.2025.10.003↗
  3. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. First author DOI 10.1016/j.xcrm.2025.102407↗
  4. Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicente… Co-author DOI 10.1186/s12893-025-02938-1↗
  5. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Co-author DOI 10.1016/s1470-2045(24)00263-8↗
  6. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline rese… Co-author DOI 10.1186/s12885-023-11327-x↗
  7. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2022.100386↗
  8. Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers13174430↗
  9. Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma. Last author DOI 10.1097/mpa.0b013e31829a80b7↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Frederik Christiaan Berrevoet · 5 shared papers, 2013–2026 · strength 0.96
  2. L.F. Abreu de Carvalho · 3 shared papers, 2025–2026 · strength 0.77
  3. Jean‐Luc Van Laethem · 4 shared papers, 2022–2025 · strength 0.70
  4. Filip Gryspeerdt · 2 shared papers, 2025–2026 · strength 0.53
  5. Emmanuel Mitry · 2 shared papers, 2024–2025 · strength 0.36
  6. Jean‐Frédéric Blanc · 2 shared papers, 2024–2025 · strength 0.36
  7. Hans Prenen · 2 shared papers, 2024–2025 · strength 0.36
  8. Lorenzo Pilla · 2 shared papers, 2024–2025 · strength 0.36
  9. Roberto Pazo-Cid · 2 shared papers, 2024–2025 · strength 0.36
  10. Aurélien Lambert · 2 shared papers, 2024–2025 · strength 0.36
  11. Jaime Feliú · 2 shared papers, 2024–2025 · strength 0.36
  12. Philippe Alexandre Cassier · 2 shared papers, 2024–2025 · strength 0.36
  13. Teresa Mercade Macarulla · 2 shared papers, 2024–2025 · strength 0.36
  14. Kathleen Claes · 2 shared papers, 2021–2025 · strength 0.29
  15. Nele Vandenbussche · 1 shared paper, 2025 · strength 0.20
  16. Eileen Mary O'Reilly · 1 shared paper, 2025 · strength 0.19
  17. Gregory Lawrence Beatty · 1 shared paper, 2025 · strength 0.19
  18. Julie Navez · 1 shared paper, 2023 · strength 0.18
  19. Jean Closset · 1 shared paper, 2023 · strength 0.18
  20. Pieter Demetter · 1 shared paper, 2023 · strength 0.18
  21. Christelle Bouchart · 1 shared paper, 2023 · strength 0.18
  22. Timon Vandamme · 1 shared paper, 2023 · strength 0.18
  23. Geert Roeyen · 1 shared paper, 2022 · strength 0.16
  24. Marc Peeters · 1 shared paper, 2022 · strength 0.16
  25. Baki Topal · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.